Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Pittsburgh
M.D. Anderson Cancer Center
Instituto do Cancer do Estado de São Paulo
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
NRG Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Duke University
Hoosier Cancer Research Network
Hoosier Cancer Research Network
Mayo Clinic
Zhejiang Haichang Biotech Co., Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Emory University
Memorial Sloan Kettering Cancer Center
Hoosier Cancer Research Network
Dana-Farber Cancer Institute
Bristol-Myers Squibb
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
ImmunityBio, Inc.
Memorial Sloan Kettering Cancer Center
University of Utah
Radboud University Medical Center
Bristol-Myers Squibb
CatalYm GmbH
Mayo Clinic
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Fox Chase Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ImmuneSensor Therapeutics Inc.
Memorial Sloan Kettering Cancer Center
The Netherlands Cancer Institute
Goethe University
Memorial Sloan Kettering Cancer Center
Emory University
The Netherlands Cancer Institute
Beth Israel Deaconess Medical Center
Ontario Clinical Oncology Group (OCOG)
Vanderbilt-Ingram Cancer Center
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Royal Marsden NHS Foundation Trust